Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers
- 176 Downloads
Alzheimer’s disease (AD) is a common age-related chronic illness with latent, prodrome, and fully symptomatic dementia stages. Increased free radical injury to regions of brain is one feature of prodrome and dementia stages of AD; however, it also is associated with advancing age. This raises the possibility that age-related free radical injury to brain might be caused in part or in full by latent AD. We quantified free radical injury in the central nervous system with cerebrospinal fluid (CSF) F2-isoprostanes (IsoPs) in 421 clinically normal individuals and observed a significant increase over the adult human lifespan (P < 0.001). Using CSF amyloid (A) β42 and tau, we defined normality using results from 28 clinically normal individuals <50 years old, and then stratified 74 clinically normal subjects ≥60 years into those with CSF that had normal CSF Aβ42 and tau (n = 37); abnormal CSF Aβ42 and tau, the biomarker signature of AD (n = 24); decreased Aβ42 only (n = 4); or increased tau only (n = 9). Increased CSF F2-IsoPs were present in clinically normal subjects with the biomarker signature of AD (P < 0.05) and those subjects with increased CSF tau (P < 0.001). Finally, we analyzed the relationship between age and CSF F2-IsoPs for those clinically normal adults with normal CSF (n = 37) and those with abnormal CSF Aβ42 and/or tau (n = 37); only those with normal CSF demonstrated a significant increase with age (P < 0.01). These results show that CSF F2-IsoPs increased across the human lifespan and that this age-related increase in free radical injury to brain persisted after culling those with laboratory evidence of latent AD.
KeywordsAlzheimer’s disease Cerebrospinal fluid Biomarkers Aβ42 Tau F2-isoprostanes
This work was supported by grants from the NIH (AG05131 and AG05136), the Fidelity Foundation, and the Nancy and Buster Alvord Endowment.
- Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., et al. (2005). Molecular, structural, and functional characterization of Alzheimer’s disease: Evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience, 25, 7709–7717.PubMedCrossRefGoogle Scholar
- Milatovic, D., VanRollins, M., Li, K., Montine, K. S., & Montine, T. J. (2005). Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by alpha- or gamma-tocopherol. Journal of chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 827, 88–93.PubMedCrossRefGoogle Scholar
- Montine, T. J., Kaye, J. A., Montine, K. S., McFarland, L., Morrow, J. D., & Quinn, J. F. (2001). Cerebrospinal fluid Aβ42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Archives of Pathology and Laboratory Medicine, 125, 510–512.PubMedGoogle Scholar
- Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina C., Chung K. A., Kim, H., Galasko, D. R., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Zhang, J. (2010). CSF Aβ42 and tau in Parkinson’s disease with cognitive impairment. Movement disorders in press.Google Scholar
- Reitan, R. M., & Wolfson, D. (1986). The Halstead-Reitan neuropsychological test battery. The neuropsychology handbook behavioral and clinical perspectives (pp. 134–160). New York: Springer Publishing Co.Google Scholar
- Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., et al. (1991). Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 88, 10540–10543.PubMedCrossRefGoogle Scholar
- Wechsler, W. (1987). Paragraph recall as well as category fluency and letter fluency Weschler memory scale. San Antonio, TX: The Psychological Corporation.Google Scholar